MetaVia (MTVA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Special Meeting scheduled for September 18, 2024, to vote on two key proposals related to recent securities offerings and warrant issuances.
Proposal 1 seeks approval for the issuance of up to 12,849,878 shares of common stock upon exercise of Series A, Series B, and Placement Agent Warrants, exceeding 20% of pre-issuance shares, as required by Nasdaq rules.
Proposal 2 authorizes adjournment of the meeting to solicit additional proxies if insufficient votes are received for Proposal 1.
Board unanimously recommends voting FOR both proposals.
Voting matters and shareholder proposals
Proposal 1: Approve issuance of shares underlying Series A, Series B, and Placement Agent Warrants, as required by Nasdaq Listing Rule 5635(d).
Proposal 2: Authorize adjournment of the Special Meeting to solicit more proxies if needed.
Only 4,949,736 shares are entitled to vote due to Nasdaq rules excluding certain recently issued shares.
Abstentions count as votes against; broker non-votes are not permitted as all matters are non-routine.
Stockholders can vote online, by phone, mail, or during the virtual meeting.
Board of directors and corporate governance
Board Chair is Andrew I. Koven; Board unanimously supports both proposals.
None of the directors or executive officers have substantial interests in Proposal 1.
Dong-A ST Co., Ltd. holds 63.22% of outstanding shares and has agreed to vote in favor of Proposal 1.
Latest events from MetaVia
- Promising obesity and MASH therapies advance with strong early data and major market potential.MTVA
Investor presentation26 Mar 2026 - Strong clinical progress and improved financials position the pipeline for key 2026 milestones.MTVA
Q4 202526 Mar 2026 - DA-1726 and vanoglipel advance in clinical trials, with key data and partnerships expected this year.MTVA
Emerging Growth Virtual Conference25 Feb 2026 - Biotech seeks $6M via unit offering to fund clinical programs, with significant dilution risk.MTVA
Registration Filing12 Jan 2026 - Biotech seeks $12.8M via unit offering to fund MASH/obesity drug trials amid ongoing losses.MTVA
Registration Filing5 Jan 2026 - 14M shares registered for resale after private placement; biotech faces ongoing losses and key risks.MTVA
Registration Filing16 Dec 2025 - Key votes include director elections, a reverse stock split, and share issuance approval tied to Dong-A.MTVA
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditor, reverse split, and major share issuance.MTVA
Proxy Filing2 Dec 2025 - Vote sought on issuing shares for warrant exercise, with major shareholder support and dilution risk.MTVA
Proxy Filing2 Dec 2025